Codexis, Inc. (CDXS)

USD 5.19

(-7.82%)

Market Cap (In USD)

422.35 Million

Revenue (In USD)

70.14 Million

Net Income (In USD)

-76.24 Million

Avg. Volume

569.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.53-6.08
PE
-
EPS
-
Beta Value
2.071
ISIN
US1920051067
CUSIP
192005106
CIK
1200375
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Stephen George Dilly MBBS, Ph.D.
Employee Count
-
Website
https://www.codexis.com
Ipo Date
2010-04-22
Details
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.